TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study
نویسندگان
چکیده
TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study Elisabeth Quoix, Lecia Sequist, John Nemunaitis, Thaddeus Beck, Piotr Jaskiewicz, Jean-Philippe Oster, Arnaud Scherpereel, Erzsébet Juhász, Zsuzsanna Mark, Rosa Alvarez, Saiama Waqar, Joseph Potz, Nandagopal Vrindavanam, Anton Melnyk, Helen Ross, Jean-Marc Limacher
منابع مشابه
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial John Nemunaitis, Zsolt Papai, Hervé Léna, Gyorgy Losonczy, Frederic Forget, Christos Chouaid, Alexandra Szczesna, Radj Gervais, Christian H Ottensmeier, Joseph Beck, Andrzej Kazarnowicz, Virginie Westeel, Didier Debieuvre, Anne Madroszyk, Enriqueta F...
متن کاملImpact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial
BACKGROUND This study describes the effect of TG4010 vaccine on Health related Quality of Life (HRQOL) in patients with stage IIIb and IV non-small-cell lung cancer (NSCLC). METHODS 148 patients with advanced NSCLC expressing MUC1 were randomly assigned to receive TG4010 plus chemotherapy or chemotherapy alone. HRQOL was assessed with the Functional Assessment of Cancer Therapy-Lung (FACT-L) ...
متن کاملViral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
BACKGROUND Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients treated with standard chemotherapy alone. Our study intended to establish the association between overall survival and vaccine-induced T cell respon...
متن کاملTg4010 Vaccine Targeting on NSCLC
Lung cancer is the most common factor of cancer-related deaths and about 85% of lung cancer is non-small cell lung cancer (NSCLC). MUC1, known as the attached protein or trans-membrane protein, is a kind of protein with highly glycosylation (greater than 50%) and high molecular weight (Mr>200*103). MUC1 is overexpressed in many malignancies, and as a tumor-associated antigens (TAAs), it exposes...
متن کاملProduction and Characterization of a Monoclonal Antibody against an Antigen on the Surface of Non-Small Cell Carcinoma of the Lung
Background: Lung carcinoma is a multiple type cancer comprising of small cell and non-small cell carcinomas (NSCLC). For therapeutic and diagnostic purposes, serum monoclonal antibodies have been produced against lung cancer. Objective: To charac-terize a murine monoclonal antibody (ME3D11) reactive with human NSCLC. Methods: A murine monoclonal antibody (ME3D11) reactive with human NSCLC was s...
متن کامل